Coherus Biosciences Reports Q1 2026 Loss of $0.25 Per Share
This article was created with the help of artificial intelligence.
Key Takeaways
- Coherus Biosciences reported on May 11, 2026 a Q1 loss of $0.25 per share versus expected loss of $0.18 per share
- The quarterly loss improved compared to the prior-year loss of $0.35 per share in Q1 2025
- The company expects revenue growth for LOQTORZI, a nasopharyngeal carcinoma drug, in the remainder of 2026
- Coherus is preparing multiple clinical data presentations from its oncology pipeline for 2026
- Q1 2026 revenues fell short of analyst expectations
Coherus Biosciences Inc. (NASDAQ: CHRS) reported on May 11, 2026 a loss of $0.25 per share for the first quarter of 2026. The result fell short of the analyst consensus estimate, which had expected a loss of $0.18 per share. In the prior-year quarter, the biotechnology company had reported a loss of $0.35 per share.
Q1 2026 revenues fell short of analyst expectations. The Redwood City, California-based company did not release detailed revenue figures in the available sources.
LOQTORZI to Drive Revenue Growth
According to statements made during the Q1 earnings call, Coherus Biosciences expects increasing revenue growth for LOQTORZI in the remainder of 2026. LOQTORZI is a drug for the treatment of nasopharyngeal carcinoma – a cancer affecting the upper throat behind the nose. Nasopharyngeal carcinoma occurs mainly in certain regions of Asia and North Africa and is less common in Europe and North America.
The company focuses on the development and commercialization of oncology therapeutics. Beyond LOQTORZI, Coherus is working on a pipeline of additional cancer drugs that are in various stages of clinical development.
Clinical Data Presentations Expected Throughout the Year
According to the company, Coherus Biosciences is preparing multiple clinical data presentations from its oncology pipeline for 2026. The company did not provide specific details during the Q1 earnings call regarding which drug candidates are in focus and when exactly the data will be released.
Clinical data presentations are critical milestones for biotechnology companies as they demonstrate whether experimental drugs achieve the desired efficacy and safety in patient studies. Positive data can form the basis for regulatory submissions to agencies such as the FDA (U.S. Food and Drug Administration).
Background on Coherus Biosciences
Coherus Biosciences is a biopharmaceutical company specializing in the development and commercialization of oncology therapeutics. The company was originally known for its biosimilars – generic versions of already-approved biologics – but has increasingly shifted its focus to innovative cancer therapies.
Coherus Biosciences stock is traded on the NASDAQ under the ticker symbol CHRS. The company is in a growth phase and invests substantial resources in research and development as well as building its commercial infrastructure.